Novartis (NYSE:NVS) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
JPM26: Vor Bio narrows focus to two-indication strategy [Yahoo! Finance]
Novartis CEO Dr. Vasant Narasimhan sits down with Jim Cramer [CNBC]
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]